Evgen Pharma plc announced the appointment of Richard Moulson, an experienced healthcare executive, as the company's Chief Financial Officer. Richard joins the company as CFO designate for a handover period to February 28, 2017, on which date John Bradshaw, the current CFO, will leave the company to focus on his work with a new healthcare investment vehicle. Richard will join the company's Board and become CFO on March 1, 2017.

He worked in corporate finance at Deutsche Morgan Grenfell for 10 years before working in financial and company secretarial roles at a number of UK biotechnology and technology companies. Since 2012, Richard has had a portfolio of interests, including recently as CFO of Cogent Breeding Limited and previously as Interim CFO of ReNeuron Group plc and Interim CFO of Enigma Diagnostics Limited. The company also announces that David Howat, holds the non-Board position of Chief Development Officer, will leave the company at the end of March 2017.

David led the preclinical and early-stage clinical development of the company's lead product through to the Phase II trials. The Phase II trials will continue to be managed by Dave Chadwick, the company's Senior Clinical Study Manager, who, on March 1, 2017, assumes the role of Head of Clinical Operations, a non-Board position.